Mo żliwości leczenia indukcyjnego chorych na szpiczaka plazmocytowego kwalifikujących się do chemioterapii wysokodawkowanej wspomaganej autologiczną transplantacją komórek krwiotwórczych a aktualne zalecenia Polskiej Grupy Szpiczakowej

Publication date: Available online 15 June 2017 Source:Acta Haematologica Polonica Author(s): Agnieszka Druzd-Sitek, Jan Walewski Despite significant progress in the treatment of multiple myeloma, it still remains an incurable disease. The introduction of new drugs has contributed to the increased overall survival of patients diagnosed with multiple myeloma and significantly improved their quality of life. Proteasome inhibitors, immunomodulators and monoclonal antibodies are often used in combination with chemotherapeutic agents. Despite the indisputable role of the new drugs for the treatment of myeloma, high-dose chemotherapy with autologous stem cell transplantation is still the method of choice in a group of younger patients without significant comorbidities. Induction treatment in myeloma patients eligible for autologous stem cell transplantation is particularly important, because the results of the first-line therapy impact further outcome of patients. The quality of the response to first-line treatment determines the progression-free survival. The choice of bortezomib, thalidomide, dexamethasone regimen as induction therapy, recommended by the Polish Myeloma Group, is in line with the recommendations of international experts. The results of the randomized clinical trials have demonstrated that the triple therapy, based on proteasom inhibitors, immunomodulators and steroids, is more effective than regimens involving two drugs only (proteasom inhibitors and steroids ...
Source: Acta Haematologica Polonica - Category: Hematology Source Type: research